Laurus Labs (LAURUSLABS) | Stock Overview & Key Data
Laurus Labs Performance Comparison
Stock Range
Today's Range
Low: ₹817.55
High: ₹840.25
on August 8, 2025
52 Week Range
Low: ₹417.70
High: ₹922.50
on August 14, 2024
on July 30, 2025
All-Time High: ₹922.50 on July 30, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR452.5B
EPS
9.45
P/E Ratio (TTM)
88.70
Forward P/E
35.87
P/B Ratio
10.11
PEG Ratio
35.87
Div. Yield
0.18%
ROE
7.79%
Beta
0.361
Debt to Equity
60.05
Financial Highlights
Profitability
Gross Margin
59.39%
Operating Margin
16.90%
Profit Margin
8.58%
Returns and Earnings
Return on Assets (TTM)
3.84%
Return on Equity (TTM)
7.79%
EBITDA
INR13.4B
Net Income (TTM)
INR5.1B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR109.94
Quarterly Revenue Growth (YoY)
31.40%
Quarterly Earnings Growth (YoY)
1,203.10%
Dividend Information
Last 12-Month Dividend
₹1.20
Current Dividend Yield
0.18%
3-Year Average Dividend Yield
0.16%
3-Year Average Annual Dividend
₹1.33
3-Year Total Dividends
₹4.00
Ex-Dividend Date
May 9, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs LAURUSLABS | 452.51B Large-cap | -3.24% | 5.60% | 40.07% | 31.21% | 33.49% | 92.79% | 45.16% | 306.88% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Cipla CIPLA | 1.20T Large-cap | -1.18% | -0.22% | -0.12% | 1.79% | 0.38% | 3.58% | 45.16% | 93.18% |
| Torrent TORNTPHARM | 1.22T Large-cap | -2.85% | 7.55% | 12.16% | 11.91% | 4.52% | 7.03% | 132.03% | 25.86% |
| Mankind Pharma MANKIND | 1.05T Large-cap | -3.87% | 1.46% | 1.13% | -1.40% | -14.37% | 15.49% | 76.92% | 76.92% |
Ownership & Short Interest
Insider Ownership
32.16%
Institutional Ownership
31.91%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
5M
Average 90-Day Volume
3M
Laurus Labs Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Laurus Labs would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is LAURUSLABS's 52-week high and low?
- In the last 52 weeks, Laurus Labs reached a high of ₹922.50 (on July 30, 2025) and a low of ₹417.70 (on August 14, 2024).
- What is the market cap and P/E ratio for LAURUSLABS?
- Curious about Laurus Labs's size and valuation? Its market capitalization stands at 452.51B. When it comes to valuation, the P/E ratio (trailing twelve months) is 88.70, and the forward P/E (looking ahead) is 35.87.
- Does LAURUSLABS pay dividends? If so, what's the yield?
- Yes, Laurus Labs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.18%, and the company has paid an average of ₹1.33 per share annually over the past 3 years.
- Who are Laurus Labs's main competitors or similar companies to consider before investing?
When looking at Laurus Labs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Cipla
CIPLA1.20T Healthcare Drug Manufacturers - Specialty & Generic 3.58% 45.16% Torrent
TORNTPHARM1.22T Healthcare Drug Manufacturers - Specialty & Generic 7.03% 132.03% Mankind Pharma
MANKIND1.05T Healthcare Drug Manufacturers - Specialty & Generic 15.49% 76.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Laurus Labs Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Laurus Labs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.79%, the Debt to Equity ratio from the most recent quarter is 60.05, and its Gross Profit Margin stands at 59.39%.
- What is the recent revenue and earnings growth for LAURUSLABS?
- Looking at Laurus Labs's growth, its revenue over the trailing twelve months (TTM) was INR59B. Compared to the same quarter last year (YoY), quarterly revenue grew by 31.40%, and quarterly earnings saw a YoY growth of 1,203.10%.
- How much of LAURUSLABS stock is held by insiders and institutions?
- Wondering who owns Laurus Labs stock? Company insiders (like executives and directors) hold about 32.16% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 31.91%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.